EVIDENCE PROFILE / PUBLISHED
IGF-1 LR3
Long R3 IGF-I is an IGF-I analogue engineered for reduced binding to IGF-binding proteins; it is not ordinary recombinant human IGF-1. No adequate controlled human administration study was identified for this analogue in the reviewed source set.
Evidence at a glance
- Human
- Not rated
- Animal/cell
- Not rated
- Approved medicine
- None foundScope: the sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. It is a laboratory probe for IGF-1 receptor signaling, growth, metabolism, and tissue responses.
Identity
Long R3 IGF-I is an IGF-I analogue engineered for reduced binding to IGF-binding proteins; it is not ordinary recombinant human IGF-1.
Biological mechanism or research interest
It is a laboratory probe for IGF-1 receptor signaling, growth, metabolism, and tissue responses.
Verified approved human uses
No approved human use for IGF-1 LR3 was verified in the reviewed sources; approvals for other IGF-1 medicines cannot be transferred.
Investigational human evidence
No adequate controlled human administration study was identified for this analogue in the reviewed source set.
Popular claims versus demonstrated findings
Muscle-growth, recovery, and anti-aging claims are not demonstrated clinical outcomes.
Human versus animal or cell evidence
The cited guinea-pig and mouse/cell studies report tissue and metabolic effects that vary by model; the recent mouse study did not preserve cognition.
Limitations and known risks
Growth signaling raises unresolved hypoglycemia, organ-growth, and tumor-biology concerns; human dosing, pharmacokinetics, and long-term safety are not established.
